Teva Pharmaceutical Industries Ltd. announced that S&P Global Ratings raised its long-term issuer credit rating to BB+ from BB with a stable outlook, while Moody's confirmed its Ba1 rating and changed the outlook to positive. The upgrades are a result of Teva's ongoing deleveraging efforts and improving operational performance. S&P noted that adjusted leverage dropped to 4.4x as of Sept. 30, 2025, with expectations of further reduction to below 4.25x in the near future, supporting the higher rating. Both agencies praised Teva's financial discipline, strong liquidity, and return to revenue growth following a five-year decline, driven by the success of branded medications and stability in generics. For more details, visit Benzinga.com.